IDEAS home Printed from https://ideas.repec.org/a/taf/ijecbs/v11y2004i2p175-195.html
   My bibliography  Save this article

Pharmaceutical R&D in the Setting of Incomplete European Integration

Author

Listed:
  • Peter Kotzian

Abstract

The article analyzes the consequences of national price regulation for newly developed medicines in the setting of a partially integrated EU-wide market for pharmaceuticals and strategic entry-decisions by pharmaceutical enterprises. EU member states can be seen as jointly contributing to financing R&D conducted by the pharmaceutical industry. The article derives and compares the welfare implications of three regimes to organize this kind of collective action. First, a situation in which each government of a EU member state grants the price for a medicine it thinks appropriate, oriented solely at domestic considerations, but there is no spill over of prices among national markets. Second, the current situation in the EU of introduced tradability for medicines while price setting remained a national competence. Third, the possible situation of a centralized price setting procedure leading to a single price with compensations for those member states unable to pay this European price. The article argues that the process of EU integration in pharmaceuticals has left an optimal state without reaching another optimal one, but is instead stuck in a state of diminished welfare for all parties concerned.

Suggested Citation

  • Peter Kotzian, 2004. "Pharmaceutical R&D in the Setting of Incomplete European Integration," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 11(2), pages 175-195.
    • Handle: RePEc:taf:ijecbs:v:11:y:2004:i:2:p:175-195
    DOI: 10.1080/1357151042000222519
    as

    Download full text from publisher

    File URL: http://www.tandfonline.com/10.1080/1357151042000222519
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1080/1357151042000222519?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Scharpf, Fritz W., 1991. "Koordination durch Verhandlungssysteme: Analytische Konzepte und institutionelle Lösungen am Beispiel der Zusammenarbeit zwischen zwei Bundesländern," MPIfG Discussion Paper 91/4, Max Planck Institute for the Study of Societies.
    2. Frank R. Lichtenberg, 1998. "Pharmaceutical Innovation, Mortality Reduction, and Economic Growth," NBER Working Papers 6569, National Bureau of Economic Research, Inc.
    3. Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
    4. Patricia Danzon, 1997. "Trade and Price Differentials for Pharmaceuticals: Policy Options," Monograph 000430, Office of Health Economics.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Peter Kotzian, 2002. "Stuck in the Middle: Welfare Effects of the European Pharmaceutical Markets' Incomplete Integration and a Possible Remedy," MZES Working Papers 59, MZES.
    2. Gianluca Baio & Laura Magazzini & Antonio Nicita & Fabio Pammolli & Massimo Riccaboni, 2003. "Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato," Working Papers CERM 0-2003, Competitività, Regole, Mercati (CERM).
    3. Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005. "The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 269-292, March.
    4. Sunde, Uwe & Cervellati, Matteo, 2007. "Human Capital, Mortality and Fertility: A Unified Theory of the Economic and Demographic Transition," CEPR Discussion Papers 6384, C.E.P.R. Discussion Papers.
    5. Antonio Cabrales, 2003. "Pharmaceutical generics, vertical product differentiation and public policy," Economics Working Papers 662, Department of Economics and Business, Universitat Pompeu Fabra.
    6. Pammolli, Fabio & Riccaboni, Massimo, 2004. "Market Structure and Drug Innovation," MPRA Paper 16212, University Library of Munich, Germany.
    7. Keith Blackburn & Niloy Bose & M. Emranul Haque, 2011. "Public Expenditures, Bureaucratic Corruption And Economic Development," Manchester School, University of Manchester, vol. 79(3), pages 405-428, June.
    8. James W. Hughes & Michael J. Moore & Edward A. Snyder, 2002. ""Napsterizing" Pharmaceuticals: Access, Innovation, and Consumer Welfare," NBER Working Papers 9229, National Bureau of Economic Research, Inc.
    9. Frances Ruane & Xiaoheng Zhang, 2007. "Where do MNEs Expand Production: Location Choices of the Pharmaceutical Industry in Europe after 1992," Papers WP211, Economic and Social Research Institute (ESRI).
    10. Chris van Egeraat & Proinnsias Breathnach, 2012. "The Drivers of Transnational Subsidiary Evolution: The Upgrading of Process R&D in the Irish Pharmaceutical Industry," Regional Studies, Taylor & Francis Journals, vol. 46(9), pages 1153-1167, October.
    11. Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
    12. Francesco Lancia & Giovanni Prarolo, 2012. "A politico-economic model of aging, technology adoption and growth," Journal of Population Economics, Springer;European Society for Population Economics, vol. 25(3), pages 989-1018, July.
    13. Desmet, Klaus & Kujal, Praveen & Lobo, Felix, 2004. "Implementing R&D policies: an analysis of Spain's pharmaceutical research program," Research Policy, Elsevier, vol. 33(10), pages 1493-1507, December.
    14. Martin Backfisch, 2018. "The Development of Firm Size and Innovativeness in the Pharmaceutical industry between 1989 and 2010," MAGKS Papers on Economics 201813, Philipps-Universität Marburg, Faculty of Business Administration and Economics, Department of Economics (Volkswirtschaftliche Abteilung).
    15. Cormac Ó Gráda, 2005. "The tortoise and the hare : economic growth in Britain and the Netherlands c.1500-1800," Working Papers 200524, School of Economics, University College Dublin.
    16. Ramón Abel Castano & David Bardey & Hernán Jaramillo & Mónica Ortegón Andrés Vecino, 2007. "¿Tiene efectos negativos el TLC sobre los precios de los medicamentos y la salud de los colombianos?," Borradores de Investigación 4362, Universidad del Rosario.
    17. Seiko Arai, 2016. "Absorptive Capability of Japanese and European MNCs: Balance between Autonomy and Control of R&D Subsidiaries in the US," GRIPS Discussion Papers 16-18, National Graduate Institute for Policy Studies.
    18. repec:dau:papers:123456789/7972 is not listed on IDEAS
    19. Dirk Czarnitzki & Katrin Hussinger & Cédric Schneider, 2011. "Commercializing academic research: the quality of faculty patenting," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 20(5), pages 1403-1437, October.
    20. Keith Blackburn & Rashmi Sarmah, 2008. "Corruption, development and demography," Economics of Governance, Springer, vol. 9(4), pages 341-362, October.
    21. Criscuolo, Paola, 2002. "Reverse Technology Transfer: A Patent Citation Analysis of the European Chemical and Pharmaceutical sectors," Research Memorandum 036, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT).

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:ijecbs:v:11:y:2004:i:2:p:175-195. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Longhurst (email available below). General contact details of provider: http://www.tandfonline.com/CIJB20 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.